Your browser doesn't support javascript.
loading
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study.
Sanborn, Rachel E; Hamid, Omid; de Vries, Elisabeth Ge; Ott, Patrick A; Garcia-Corbacho, Javier; Boni, Valentina; Bendell, Johanna; Autio, Karen A; Cho, Daniel C; Plummer, Ruth; Stroh, Mark; Lu, Lawrence; Thistlethwaite, Fiona.
Afiliação
  • Sanborn RE; Department of Medical Oncology, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA Rachel.Sanborn@providence.org.
  • Hamid O; Department of Medical Oncology, The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, California, USA.
  • de Vries EG; Department of Medical Oncology, Universitair Medisch Centrum Groningen, University of Groningen, Groningen, Netherlands.
  • Ott PA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Garcia-Corbacho J; Department of Medical Oncology, Hospital Clinic Barcelona/IDIBAPS, Barcelona, Spain.
  • Boni V; Department of Medical Oncology, START Madrid-CIOCC, Hospital Universitario HM Sanchinarro, Madrid, Spain.
  • Bendell J; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee, USA.
  • Autio KA; Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Cho DC; Department of Medicine, Perlmutter Cancer Center at NYU Langone Medical Center, New York, New York, USA.
  • Plummer R; Department of Medical Oncology, Northern Centre for Cancer Care, Newcastle Hospitals NHS Trust and Newcastle University, Newcastle upon Tyne, UK.
  • Stroh M; CytomX Therapeutics Inc, South San Francisco, California, USA.
  • Lu L; CytomX Therapeutics Inc, South San Francisco, California, USA.
  • Thistlethwaite F; Department of Medical Oncology, The Christie Hospital NHS Foundation Trust and University of Manchester, Manchester, UK.
J Immunother Cancer ; 9(7)2021 07.
Article em En | MEDLINE | ID: mdl-34301808
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Antígeno B7-H1 / Neoplasias Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Immunother Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Antígeno B7-H1 / Neoplasias Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Immunother Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Reino Unido